Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
20% SBE-β-CD in saline: Guidelines (Following is our recommended protocol
Cefoselis hydrochloride exhibits good activity against a wide range of Gram-positive and Gram-negative organisms
also acting as a CNS stimulant and exerts a positive chronotropic and inotropic effect on the heart
2014 Mar 18
SU14813 maleate - CAS# 849643-15-8 Size:Solid 10 mg 20% SBE-β-CD in saline: GuidelinesSU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet derived growth factor receptors (PDGFR), KIT, and fms like tyrosine kinase 3 (FLT 3) (1). SU14813 was developed as a next generation TKI agent following sunitinib (SU11248) designed to demonstrate optimized pharmacokinetic (PK) and tolerability profiles. SU14813 demonstrated broad and potent antitumor activity
US$ 1198.50
US$ 962.00
US$ 24.00